Continuing Skin Substitute Applications When a Wound Is Not Healing

A diabetic foot ulcer or venous leg ulcer does not always close on the timeline a skin substitute graft's labeling expects. When a provider keeps applying the graft past that point, the medical record carries the burden of showing the treatment remains reasonable and necessary. Medicare contractors and commercial reviewers read a series of flat, unchanging measurements very differently than one showing incremental progress. The difference between a defensible continuation and a recoupment demand is rarely the clinical judgment itself. It is whether that judgment was written down.

The Mid-Course Decision Every Wound Care Provider Faces

At some point in a course of skin substitute applications, a wound does not look like the case study on the product's label. Granulation is slow, epithelialization has stalled, or the wound measures the same as it did two applications ago. The treating physician then chooses to continue the same product, switch to a different skin substitute, or stop and return to debridement, offloading, compression, or a surgical referral. None of those options defends itself; the chart entry made at that visit is what later proves which choice was made and why.

What the Record Must Show to Support Continuing

Continuing applications after a wound stops closing on schedule is supportable when the record shows measured progress, or a documented reason to expect it: the wound's length, width, and depth at each application, compared to the prior visit and to baseline, not to a percentage invented after the fact. When measurements have flattened, the entry should say why treatment is still reasonable: an infection resolved, offloading finally achieved, or new granulation at the margin. Every measurement needs the clinician's contemporaneous signature, tracked the same way any other entry belongs in the practice's signature log, because a late-dated measurement carries little weight against a claim it was added afterward.

Documenting the Decision to Change Product or Stop

When serial measurements show no real trajectory toward closure, the standard of care that preceded the first application generally has to resume rather than sit idle once grafting began, and the record should show it was reconsidered, not abandoned. Switching products is defensible when the entry explains what the new product is expected to do that the prior one did not. Stopping and referring for vascular evaluation or surgical closure is also a legitimate outcome, but only if the chart shows that decision was made, not merely that the applications stopped.

How a Reviewer Reads a Record of Flattening Progress

A Medicare contractor or commercial payer reads the series of applications together, and a flat trend with unchanged notes is one of the patterns wound care audits are built to flag. The Department of Justice's December 2025 settlement with the owners of an Arizona wound graft company, who agreed to pay $309M after sales representatives ordered amniotic skin substitute grafts sized to the bill rather than the wound, and nurse practitioners were required to apply every graft ordered regardless of medical necessity, is the extreme version of the same pattern. Most continuation decisions are legitimate judgment calls, but the record that supports one looks nothing like the record that does not, and that gap can turn a routine review into a False Claims Act case.

The Continuation Standard Differs by Medicare Contractor

The documentation standard is not uniform nationwide. On December 24, 2025, CMS's Medicare Administrative Contractors withdrew the finalized local coverage determinations scheduled to take effect January 1, 2026, before those determinations ever applied to a claim. Where a contractor still has its own local coverage determination governing skin substitute grafts, that policy defines what counts as a lack of improvement. Where none exists, the contractor evaluates continued applications case by case under the general Medicare reasonable-and-necessary standard, and a practice billing across more than one jurisdiction cannot assume one contractor's documentation satisfies another.

A chart that keeps applying the same product without ever recording why is the same record a reviewer uses to argue the applications were never reasonable and necessary in the first place.

Why Early Legal Counsel Is Critical

It is critical that wound care providers retain experienced healthcare defense counsel before a documentation gap becomes an overpayment demand or a broader audit. Early legal involvement identifies where the record does not yet support the applications billed, corrects the gap before a payer has flagged the claims, and preserves the provider's position if a contractor later reviews the file. Waiting until a recoupment notice arrives narrows the options considerably.

How Health Law Alliance Can Help

Health Law Alliance has handled 5,000+ matters across healthcare regulatory and audit defense over 25+ years, including skin substitute and cellular tissue-based product claims reviewed for medical necessity. If your practice is weighing whether to continue, change, or stop a course of applications, or has already received an audit notice, contact Health Law Alliance's wound care audit defense attorneys for a free, confidential consultation.